Gulhane Medical Faculty, Department of Pulmonary Diseases, Ankara;
Onco Targets Ther. 2012;5:385-90. doi: 10.2147/OTT.S32888. Epub 2012 Nov 22.
Both of the diagnosis and treatment evaluation are time-consuming conditions in patients with pulmonary and pleural tuberculosis. The aim of this study was to establish the validity of tumor markers CA 125, CA 15-3, and CA 19-9 in the diagnosis of pulmonary and pleural TB and to verify the success of the treatment protocol.
The levels of tumor markers CA 125, CA 15-3, and CA 19-9 were measured before and after treatment in 67 TB patients, 54 of whom had pulmonary TB and 13 of whom had pleural TB. All values were compared with the results of a healthy control group of 44 subjects.
CA 125 and CA 15-3 levels were significantly high when compared with those of the healthy control group and there was a significant decrease in both tumor marker levels after treatment in patients with pulmonary TB (P < 0.001 and P < 0.004, respectively). However, the difference found in CA 19-9 levels before and after treatment in patients with pulmonary TB was not statistically significant (P < 0.08). When the CA 125, CA 15-3, and CA 19-9 values of the pulmonary TB group before treatment were compared with that of the healthy control group, the results were statistically significant in all parameters except CA 19-9 (P < 0.001, P < 0.001, and P < 0.09 for CA 125, CA 15-3, and CA 19-9, respectively). In the patients with pleural TB, CA 125, CA 15-3, and CA 19-9 values did not change significantly after treatment.
The authors suggest that CA 125 and CA 15-3 tumor markers may be important for verification of the success of treatment protocol in pulmonary TB, as the differences found for these tumor markers between the pre- and the posttreatment periods are statistically significant.
肺结核和胸膜结核患者的诊断和治疗评估都是耗时的过程。本研究的目的是确定肿瘤标志物 CA 125、CA 15-3 和 CA 19-9 对肺结核和胸膜结核的诊断价值,并验证治疗方案的疗效。
在 67 例 TB 患者(其中 54 例患有肺结核,13 例患有胸膜炎)中,测量了治疗前后肿瘤标志物 CA 125、CA 15-3 和 CA 19-9 的水平。所有值均与 44 名健康对照组的结果进行了比较。
与健康对照组相比,CA 125 和 CA 15-3 水平显著升高,且肺结核患者治疗后两种肿瘤标志物水平均显著下降(P<0.001 和 P<0.004)。然而,肺结核患者治疗前后 CA 19-9 水平的差异无统计学意义(P<0.08)。当比较肺结核组治疗前的 CA 125、CA 15-3 和 CA 19-9 值与健康对照组时,除 CA 19-9 外,所有参数均有统计学意义(CA 125、CA 15-3 和 CA 19-9 的 P 值分别为<0.001、<0.001 和<0.09)。在胸膜炎患者中,治疗后 CA 125、CA 15-3 和 CA 19-9 值无明显变化。
作者认为 CA 125 和 CA 15-3 肿瘤标志物可能对验证肺结核治疗方案的疗效很重要,因为这些肿瘤标志物在治疗前后的差异具有统计学意义。